evipedia.ai
← Back

Picamilon for Health & Longevity

Evidence Review created on 09/28/2026 using AI4L / Opus 5.5

Also known as: Pikamilon, Picamilone, Pikamilone, Pycamilon, Pikatropin, Nicotinoyl-GABA, Nicotinyl-GABA, N-nicotinoyl-GABA, Nicotinoyl gamma-aminobutyric acid, Nicotinyl-gamma-aminobutyric acid, N-nicotinoyl-γ-aminobutyric acid, 4-(pyridine-3-carbonylamino)butanoic acid, Amilonosar, Ceregamon

Motivation

Picamilon (also sold as pikamilon) is a synthetic compound made by chemically joining niacin, a B vitamin, to the brain’s main calming chemical messenger. On its own, that messenger passes poorly from the blood into the brain; picamilon was designed to carry it across. Health-focused adults are interested in it as a possible way to support memory and calm focus with advancing age.

Developed in the Soviet Union around 1970, picamilon has long been a prescription medication in Russia, used for reduced blood flow to the brain and anxiety. In the United States it spread through “brain-boosting” products until federal regulators stated in 2015 that it cannot lawfully be sold as a dietary supplement. Most of its clinical research is in Russian, and recent studies have focused on older adults with memory complaints linked to blood-vessel disease of the brain.

This review examines what human, animal, and laboratory evidence shows about picamilon’s effects on thinking and mood, its side effects, its legal status and product quality, and how it is dosed and monitored with healthy aging in mind.

Benefits - Risks - Protocol - Conclusion

This section lists high-level overviews and key primary papers on picamilon’s history, mechanism, and product quality.

Only four items qualified: most other picamilon content online consists of vendor pages, encyclopedias, or news reports, and the list is not padded with marginally relevant material. No directly relevant picamilon content was found from Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, or Lifespan.io; searches of their platforms returned no articles or episodes on the compound.

Grokipedia

  • Picamilon

    An AI-generated encyclopedia entry covering chemistry, Soviet development, Russian indications, and U.S. regulatory status. Useful for orientation, but some safety statements (e.g., liver toxicity at high doses) lack cited human evidence.

Examine

No Examine article on picamilon exists. Examine.com does not typically cover prescription medications, and picamilon is a prescription drug in Russia and an unapproved drug in the United States.

ConsumerLab

Systematic Reviews

No systematic reviews or meta-analyses for Picamilon were found on PubMed as of 09/28/2026.

Mechanism of Action

Picamilon is nicotinic acid (niacin) joined to GABA by an amide bond (a stable chemical link). It was designed as a prodrug (an inactive carrier converted into active compounds in the body), because GABA itself crosses the blood-brain barrier (the protective filter between blood and brain) poorly.

  • Prodrug hypothesis: Soviet studies detected picamilon in rat brain within 30 minutes (Kruglikova overview, Life Extension) and proposed that amidases (enzymes that split amide bonds) release GABA and niacin there, calming overactive nerve cells and widening brain blood vessels.
  • Vascular action: In animals, picamilon increased brain blood flow and blunted sympathetic (fight-or-flight) nerve-driven vessel spasm (Mirzoian & Gan’shina, 1989); blocking the chloride channel of the GABA-A receptor (the main calming receptor) with picrotoxin (a channel-blocking toxin) weakened this effect (Silkina et al., 2005).
  • Competing evidence: A Japanese mouse study found only a slight rise in brain GABA after very high doses (Matsuyama et al., 1984), and an FDA screen found intact picamilon bound none of 50 targets (Santillo & Sprando, 2023). Meaningful GABA release in humans is unproven.
  • Pharmacology: Absorption is rapid (peak about 14 minutes in animals); oral bioavailability (share reaching the blood) was 22% in mice and 53–79% in rats; elimination half-life (time for levels to halve) was about 0.5 hours, mostly as unchanged drug in urine (Dorofeev & Kholodov, 1991). It distributes widely into tissues, shows no selective high-affinity target, and no cytochrome P450 (CYP, the liver’s main drug-processing enzymes) metabolism has been described.

Historical Context & Evolution

Picamilon was synthesized around 1969–1970 at the All-Union Vitamin Research Institute in Moscow, part of a Soviet effort to attach GABA to vitamins so that it could reach the brain. Its original intended use was as a cerebrovascular drug (one that improves brain blood flow) and a daytime tranquilizer that avoids drowsiness. Animal work showed increased brain blood flow, calming effects at low doses, and stimulation at high doses. Soviet clinical programs in 984 patients with stroke after-effects, chronic brain blood-flow insufficiency, anxiety, depression, and alcohol withdrawal reported better mood, memory, and sleep, though without published control groups (Kruglikova overview, Life Extension). It entered Soviet practice in the late 1980s and remains a prescription drug in Russia.

It came to be considered for health optimization in the 1990s, when Life Extension, which also sells supplements, presented Russian drugs to Western readers as brain-protective, and later when nootropic communities adopted it as a route to GABA effects. By the 2010s it was widely sold in U.S. supplements.

Opinion shifted in 2015 on regulatory and quality grounds rather than new efficacy data: researchers documented inaccurate supplement labels (Avula et al., 2016), Oregon’s Attorney General sued a major retailer, and the FDA declared picamilon not a dietary ingredient. Since then, Russian trials without placebo groups have added modest human data (Danilov et al., 2024), while an FDA binding screen (Santillo & Sprando, 2023) raised new questions about how it works.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: the only randomized human trial with a non-picamilon comparator is a single open-label (patients and doctors knew the treatment) add-on study, and the remaining human data are regimen comparisons and case series without a non-picamilon control group.

Medium 🟩 🟩

Improved thinking scores in vascular cognitive impairment

In a randomized, open-label trial funded by the Russian manufacturer Pharmstandard, 278 adults over 45 with chronic cerebral ischemia (long-term reduced brain blood flow) took picamilon plus ginkgo or ginkgo alone for 90 days (Zakharov et al., 2022). The picamilon group gained more on the MoCA (Montreal Cognitive Assessment, a 30-point thinking test) and quality-of-life scores. A trial comparing two picamilon regimens, without a non-picamilon control, showed similar within-person gains (Danilov et al., 2024). No blinded or healthy-adult data exist.

Magnitude: Extra MoCA gain of 0.66 points (95% CI (confidence interval, the range likely to contain the true effect) 0.33–1.00) versus ginkgo alone at 90 days, and 1.62 points in people with high blood pressure; in a regimen-comparison trial without a non-picamilon control, MoCA rose from 24.9 to 28.3 points.

Low 🟩

Better sleep quality and fewer autonomic symptoms

Two Russian studies of adults with chronic cerebral ischemia reported better sleep questionnaire scores and fewer autonomic (involuntary nervous system) complaints, such as headache, over 60–70 days (Danilov et al., 2024; Danilov et al., 2024). Neither had a non-picamilon control group.

Magnitude: Sleep score rose from 19.7 to 24.3 of 30 points, sleep quality improved in 84% of patients by 1.5 months after treatment, and autonomic function normalized in 29–38%.

Reduced fatigue and anxiety

Soviet programs reported less anxiety, irritability, and fatigue, including apathy and lethargy during alcohol withdrawal, without control groups (Kruglikova overview, Life Extension). A Russian review supports use in asthenia (chronic weakness and fatigue) (Titova et al., 2023). The randomized trial found no depression-score difference (Zakharov et al., 2022).

Magnitude: Uncontrolled Soviet series describe reduced anxiety and fatigue during 2-week to 1.5-month courses of 40–300 mg/day in patients with anxiety, asthenia, or alcohol withdrawal (Kruglikova overview, Life Extension); the literature reports no fatigue- or anxiety-specific outcome figure.

Preserved visual function in eye disease ⭕️ Not Central to Health & Longevity

Russian reports describe wider visual fields and better contrast sensitivity in glaucoma (optic nerve damage) and retinal degenerations (Kolomoitseva et al., 1994; Davydova & Mukha, 1995; Basinskii et al., 2001). Designs were small and mostly uncontrolled. It bears on disease-specific vision preservation.

Magnitude: Visual parameters improved in 65% of patients taking tablets in an uncontrolled 48-patient series of central retinal degeneration (Basinskii et al., 2001).

Improved bladder function ⭕️ Not Central to Health & Longevity

Small uncontrolled Russian studies reported better urinary symptom scores and flow in older men with benign prostatic hyperplasia (non-cancerous prostate enlargement) and better bladder storage in children when combined with bladder-relaxing drugs (Tolstova, 1999; Vishnevskii & Guseva, 1998). It bears on bladder disorders.

Magnitude: Maximal and mean urinary flow rates increased while residual urine volume stayed unchanged in men with prostate enlargement; the abstracts report no outcome figures.

Speculative 🟨

Increased brain blood flow

Animal studies show increased brain blood flow (Mirzoian & Gan’shina, 1989); human series report faster blood flow in brain arteries and improved blood-vessel-lining markers (Danilov et al., 2024). These are unvalidated surrogate markers.

Brain protection after low oxygen or injury

Rodent studies report longer survival under low oxygen and protected brain mitochondria (cell energy producers) after head injury (Karaev et al., 1989; Novikov & Kovaleva, 1998). The basis is animal data only.

Physical work capacity and recovery

Soviet rat studies reported faster recovery of work capacity (Kruglikova overview, Life Extension); a study in swimmers measured only brain blood-filling patterns (Likhodeev et al., 2009). No human performance outcome has been measured.

Protection against diabetic nerve damage ⭕️ Not Central to Health & Longevity

In diabetic rats, picamilon reduced nerve sugar-alcohol buildup, raised myelin (nerve insulation) protein, and lowered blood glucose (Kuchmerovska et al., 2024). Basis is animal data; it bears on diabetes complications.

Migraine prevention ⭕️ Not Central to Health & Longevity

Russian labeling lists add-on migraine prevention (Vidal drug monograph); no human outcome data exist, and rats showed no serotonin-transport effect (Pukhal’skaia et al., 1989). It bears on headache disorders.

Benefit-Modifying Factors

  • Genetic polymorphisms: No study has examined gene variants affecting picamilon response; variants in GABA-A receptor subunits or amide-splitting enzymes are plausible but untested modifiers.
  • Baseline cognitive status: Patients with more advanced chronic cerebral ischemia and lower starting MoCA scores showed larger average gains (Danilov et al., 2025); cognitively healthy adults may have little room to improve.
  • Baseline vascular markers: Improvements in blood-vessel-lining markers occurred in patients whose levels started above normal (Danilov et al., 2024); people with normal baseline values have no demonstrated vascular benefit.
  • Blood pressure: In the randomized trial, patients with hypertension (high blood pressure) showed a larger extra cognitive gain than the whole group (Zakharov et al., 2022), suggesting a vascular component.
  • Sex: No sex-specific analyses exist; one regimen-comparison trial was 93% women (41 of 44) (Danilov et al., 2024), limiting conclusions for men.
  • Pre-existing conditions: Human benefit data come almost entirely from people with vascular brain disease, fatigue disorders, or eye and bladder disease; no trial has tested picamilon in healthy adults seeking prevention.
  • Age: Trials enrolled adults over 45, with Russian series spanning ages 46–69 (mean ages 55–62) (Danilov et al., 2024; Danilov et al., 2024); Russian labeling covers late-life depression, but no data isolate responses in adults over 75.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: adverse-event data come from one open-label randomized trial with a non-picamilon comparator, studies without a non-picamilon control, and Russian prescribing information, not from multiple controlled trials with systematic safety reporting.

Medium 🟥 🟥

Flushing and unstable blood pressure

Picamilon widens blood vessels and lowered blood pressure in animals, and any nicotinic acid split off in the body could add flushing, although such release in humans is unproven (Kruglikova overview, Life Extension). In the 278-patient randomized trial, investigators attributed a feeling of heat to the head and unstable blood pressure to the picamilon-ginkgo product (Zakharov et al., 2022). Events were mild and resolved without treatment, and unstable blood pressure also occurred on ginkgo alone.

Magnitude: These events fall within the 7 drug-related events among 139 patients at 60 mg/day; the trial reports no separate figure for flushing or blood-pressure events.

Low 🟥

Headache, dizziness, irritability, and drowsiness ⚠️ Conflicted

Russian labeling lists irritability, agitation, anxiety, dizziness, headache, and nausea (Vidal drug monograph). In the randomized trial, drug-related events on picamilon-ginkgo, including headache and drowsiness, numbered 7 versus 24 on ginkgo alone (Zakharov et al., 2022). On balance, these effects occur, but the only controlled comparison showed no excess.

Magnitude: 7 drug-related adverse events among 139 treated patients (about 5 per 100) over 90 days; total adverse events below 8.6% in a trial without a non-picamilon control (Danilov et al., 2024).

Allergic skin reactions

Russian prescribing information lists skin rash and itching (Russian prescribing information, Vidal drug monograph). Published series report good tolerability without itemizing allergic events (Danilov et al., 2024).

Magnitude: Not quantified in available studies. The prescribing information gives no frequencies, and trial reports do not itemize allergic reactions.

Speculative 🟨

Inaccurate dosing and undeclared drugs in supplements

U.S. supplements delivered 2.7–721.5 mg picamilon daily (Avula et al., 2016); cognitive products held undeclared drugs such as phenibut (a GABA-like anti-anxiety drug) (Cohen et al., 2021). The basis is product testing only.

Kidney injury at high doses

A six-month rat study found glomerulonephritis (kidney filter inflammation) and nephrosclerosis (kidney scarring) at 15 times the therapeutic dose (Kruglikova overview, Life Extension). No human kidney signal is reported.

Stimulation at high doses

In animals, high doses (80–160 mg/kg) produced amphetamine-like stimulation and shortened barbiturate (older sedative drug) sleep, whereas low doses were calming (Kruglikova overview, Life Extension). Human relevance is unknown.

Pregnancy and breastfeeding exposure

No human data exist. Russian labeling contraindicates use (Russian prescribing information, Vidal drug monograph), although Soviet animal studies reported no teratogenic (birth-defect-causing) effects (Kruglikova overview, Life Extension).

Risk-Modifying Factors

  • Genetic polymorphisms: No pharmacogenetic (gene-based drug response) data exist; because no CYP metabolism is described, common drug-metabolism gene variants are unlikely modifiers.
  • Kidney function: Picamilon is cleared largely unchanged by the kidneys; a low eGFR (estimated glomerular filtration rate, a blood-test estimate of kidney filtering) may raise exposure, and chronic kidney failure is a labeled contraindication.
  • Baseline blood pressure: People with low or fluctuating blood pressure may be more prone to lightheadedness from vasodilation (blood-vessel widening).
  • Sex: No sex differences in adverse events are reported; pregnancy and breastfeeding are labeled contraindications.
  • Pre-existing conditions: Kidney disease, hypotension (low blood pressure), and hereditary sugar-intolerance disorders (tablets contain sucrose) raise risk; people taking sedatives or opioids (strong pain medications) face interaction risks.
  • Age: Adults over 65 more often have reduced kidney function and take sedating drugs, increasing exposure and fall risk; no age-specific safety data exist.

Key Interactions & Contraindications

  • Opioid analgesics (strong pain medications such as morphine, oxycodone, tramadol) — caution: Russian labeling states picamilon strengthens opioid effects, risking excess sedation or slowed breathing. Mitigation: combined use is typically limited to prescriber-supervised settings.
  • Barbiturates (older sedative and seizure drugs such as phenobarbital) — monitor: Labeling states picamilon shortens barbiturate action, potentially weakening seizure or sedation control. Mitigation: drug response is monitored with the prescriber.
  • Benzodiazepines and sleep drugs (anti-anxiety sedatives such as alprazolam, diazepam; zolpidem) — caution: Theoretical additive calming and drowsiness. Mitigation: the lowest picamilon dose and no bedtime co-dosing until tolerance is known reduce this risk.
  • Blood-pressure-lowering drugs (amlodipine, lisinopril, losartan), nitrates (vessel-widening chest-pain drugs such as nitroglycerin, isosorbide mononitrate), and PDE5 inhibitors (vessel-widening erectile dysfunction medications such as sildenafil) — monitor: Additive vasodilation may cause lightheadedness or low blood pressure. Mitigation: daily home blood-pressure checks for two weeks.
  • Antiplatelet drugs and anticoagulants (blood thinners such as aspirin, clopidogrel, warfarin, apixaban) — caution: Labeling describes reduced platelet clumping; theoretical increased bruising or bleeding. The randomized trial excluded these users (Zakharov et al., 2022). Mitigation: watching for bleeding and informing clinicians before procedures.
  • Over-the-counter medications — monitor: Sedating antihistamines (diphenhydramine, doxylamine) may add drowsiness; NSAIDs (non-steroidal anti-inflammatory pain medications such as ibuprofen, naproxen) may add bleeding tendency. Mitigation: separating use from sedating antihistamines.
  • Calming supplements (phenibut, GABA, kava, valerian, melatonin) — caution: Additive calming or drowsiness; phenibut is itself an unapproved drug often co-sold in cognitive products. Mitigation: not combining multiple calming agents.
  • Niacin supplements — monitor: Picamilon’s nicotinic acid portion is about 59% of its weight, though release in humans is unproven; added high-dose niacin increases flushing and, above 1–2 g/day, liver strain. Mitigation: tallying total nicotinic acid intake.
  • Vasodilating supplements (Ginkgo biloba, vinpocetine) — monitor: Additive blood-vessel widening and possible bleeding tendency; a Russian picamilon-ginkgo product reported no serious events (Zakharov et al., 2022). Mitigation: watching for headache and easy bruising.
  • Alcohol — caution: Soviet use in alcohol withdrawal does not establish safety with ongoing drinking; combined calming effects are untested. Mitigation: limiting alcohol during use.

Populations who should avoid Picamilon:

  • Chronic kidney disease stage 3–5 (eGFR below 60 mL/min/1.73 m²), a conservative reading of the labeled “chronic renal failure” contraindication
  • Pregnancy and breastfeeding
  • Known hypersensitivity to picamilon
  • Hereditary fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase deficiency (inherited disorders of sugar digestion or absorption), because tablets contain sucrose
  • Children and adolescents under 18 outside specialist care
  • Symptomatic hypotension (resting systolic blood pressure below 90 mmHg)
  • U.S. military service members (picamilon is on the Department of Defense prohibited-ingredient list)

Risk Mitigation Strategies

  • Low starting dose with slow titration: Protocols typically begin at 20–50 mg once daily for 3–5 days, then increase to 50 mg two to three times daily, limiting headache, dizziness, and irritability.
  • Pharmaceutical-grade products: Registered Russian 20 or 50 mg tablets, unlike U.S. supplements, avoid the 2.7–721.5 mg dose spread and undeclared drugs found in testing.
  • Kidney check before starting: A baseline eGFR, with no use below 60 mL/min/1.73 m², prevents drug accumulation given kidney clearance.
  • Blood pressure tracking: Daily home blood pressure for 2 weeks, stopping if systolic falls below 90 mmHg or dizziness on standing occurs, prevents hypotension-related falls.
  • No sedative combinations: Not combining with opioids, benzodiazepines, phenibut, or alcohol prevents excess sedation and slowed breathing.
  • Course-limited use: 1–2-month courses with 5–6-month breaks limit unknown long-term exposure.
  • Early stop for skin reactions: Stopping at the first rash or itching prevents progression of allergic reactions.

Therapeutic Protocol

  • Russian prescribing standard: 20–50 mg orally 2–3 times daily (60–150 mg/day) for 1–2 months, with a repeat course after 5–6 months (Russian prescribing information, Vidal drug monograph).
  • Clinical-trial regimens: 50 mg three times daily for 60 days (Danilov et al., 2024); the combination product supplied 20 mg picamilon with 40 mg ginkgo three times daily for 90 days (Zakharov et al., 2022).
  • Anti-fatigue and anti-anxiety dosing: Russian labeling lists 40–80 mg/day, up to 200–300 mg/day, for 1–1.5 months.
  • Self-directed nootropic approach: Popularized in the U.S. by Life Extension (a supplement seller) in 1997 and later by Nootropics Expert, an affiliate-funded site citing 50 mg two to three times daily, up to 100 mg per dose.
  • Time of day: Doses are spread across the day and may be taken regardless of meals. People noticing stimulation often avoid late-evening doses, although trials reported improved sleep.
  • Half-life: Animal elimination half-life is about 0.5 hours; human data are limited to an assay study in volunteers (Cui et al., 2010). Tissue retention may extend action beyond blood levels.
  • Single versus split doses: Because of the short half-life, all studied regimens split the daily amount into 2–3 doses.
  • Genetic polymorphisms: No gene variant is known to alter picamilon dosing, and no pharmacogenetic test has been studied for it.
  • Sex: No sex-specific dosing exists; one regimen-comparison trial was 93% women (Danilov et al., 2024), and pregnancy or breastfeeding excludes use.
  • Age: For late-life depression, labeling uses 60–120 mg/day; older adults commonly start at the low end given age-related kidney decline.
  • Baseline biomarkers: Russian labeling contraindicates chronic kidney failure, and low blood pressure raises lightheadedness risk; lower baseline cognitive scores predicted larger gains in Russian series (Danilov et al., 2025).
  • Pre-existing conditions: People with hypertension showed larger cognitive gains in the randomized trial (Zakharov et al., 2022); kidney disease precludes use.

Discontinuation & Cycling

  • Short-term by design: Russian practice uses 1–2-month courses rather than lifelong use; continuous long-term use has not been studied.
  • Withdrawal effects: None are reported in Russian labeling or trials; unlike phenibut, no dependence or rebound anxiety reports appear in the literature.
  • Tapering: Labeling requires no taper; people using more than 150 mg/day sometimes halve the dose for 3–7 days before stopping as a precaution.
  • Cycling: Labeling recommends repeat courses after 5–6 months; in one series, cognitive and sleep gains persisted and grew for 1.5 months after stopping (Danilov et al., 2024).

Sourcing and Quality

  • U.S. legal status: The FDA considers picamilon not a dietary ingredient, so U.S. products labeled as supplements are misbranded (FDA: Picamilon in Dietary Supplements).
  • Pharmaceutical products: Registered Russian tablets (20 mg and 50 mg sodium salt) are made by Pharmstandard; analog brands include Amilonosar (Promomed) and Ceregamon (Marbiopharm) (Russian prescribing information, Vidal drug monograph).
  • Label inaccuracy: In U.S. testing, one of 31 products contained no detectable picamilon and daily amounts ranged from 2.7 to 721.5 mg (Avula et al., 2016).
  • Undeclared co-ingredients: Cognitive products contained unapproved drugs such as phenibut, vinpocetine, and omberacetam, some undeclared (Cohen et al., 2021).
  • Third-party testing: Supplement certification seals cannot lawfully cover picamilon; reputable bulk powders carry a batch certificate of analysis based on liquid chromatography (a standard laboratory separation test), ideally confirmed by an independent laboratory.
  • Formulation: Tablets contain sucrose and starch; oral-solution and injectable forms exist in Russia, but injections require clinical supervision.

Practical Considerations

  • Time to effect: Cognitive differences versus ginkgo alone appeared by day 30 (Zakharov et al., 2022); sleep improvements began within 10 days, and gains continued up to 1.5 months after a 60-day course (Danilov et al., 2024).
  • Common pitfalls: Assuming picamilon acts like phenibut or GABA powders, combining calming agents, trusting supplement labels, expecting immediate effects, and overlooking kidney status.
  • Regulatory status: Prescription drug in Russia; not approved as a drug in the U.S., declared not a dietary ingredient by the FDA in 2015, and prohibited for U.S. military service members.
  • Cost and accessibility: Russian tablets are inexpensive, but lawful access outside Russia and neighboring countries is difficult; U.S. availability relies on gray-market sellers of uncertain quality.
  • Language barrier: Nearly all clinical studies are in Russian with English abstracts only, limiting independent scrutiny.

Interaction with Foundational Habits

  • Sleep: Potentiating (indirect): Russian series reported improved sleep questionnaire scores (Danilov et al., 2024), likely through calming and autonomic effects. High animal doses were stimulating, so taking the last dose by mid-afternoon is a common adjustment if restlessness appears; combining with sleep drugs adds sedation.
  • Nutrition: Possibly direct but minor: each 100 mg contains about 59 mg of bound nicotinic acid, but it is mostly excreted unchanged, so its contribution to niacin intake is unproven. No food interaction is known, and it can be taken with or without meals. Tablets contain small amounts of sucrose.
  • Exercise: Possibly potentiating recovery (unconfirmed): Russian labeling lists 60–80 mg/day for two weeks for athlete recovery, based on rat work-capacity studies (Kruglikova overview, Life Extension); human performance outcomes are unmeasured. Mild blood-pressure lowering warrants care with dehydration or heat.
  • Stress management: Potentiating: designed as a daytime anti-anxiety agent without muscle relaxation or drowsiness, and animal studies show dampened stress responses (Kruglikova overview, Life Extension). It may complement, not replace, meditation or breathing practices; no cortisol (stress hormone) data exist.

Monitoring Protocol & Defining Success

Before starting, baseline testing establishes kidney clearance capacity, blood pressure, and personal reference points for thinking and sleep: an eGFR, serum creatinine, and urine albumin test; seated and standing blood pressure; a MoCA score; and a validated sleep questionnaire. Russian labeling lists chronic kidney failure as a contraindication, and low blood pressure raises the risk of lightheadedness.

Ongoing monitoring follows the course structure: home blood pressure daily during the first 2 weeks, then weekly; a symptom review at 2 and 4 weeks; repeat MoCA and sleep questionnaire at the end of each 1–2-month course and again 6 weeks after stopping; and kidney tests every 6–12 months for anyone repeating courses. Success means a measurable gain over personal baseline, for example 1–2 MoCA points or a clearly better sleep score, without adverse effects.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Estimated glomerular filtration rate ≥90 mL/min/1.73 m² Kidneys clear the drug Conventional normal ≥60; values below 60 fall under a conservative reading of the labeled kidney contraindication. No fasting needed; often paired with cystatin C (a second kidney marker) in muscular adults
Serum creatinine 0.7–1.0 mg/dL (men), 0.6–0.9 mg/dL (women) Feeds the kidney estimate Conventional upper limit about 1.3 mg/dL; intense exercise or large meat meals in the 24 hours before testing can raise results
Urine albumin-to-creatinine ratio <10 mg/g Early kidney damage Conventional cutoff <30 mg/g; first-morning urine sample preferred
Seated and standing blood pressure 110–120 / 70–80 mmHg; standing drop <20 mmHg systolic Detects excess vessel widening Conventional normal <120/80 mmHg; typically measured in the morning before dosing, then after 1–3 minutes standing
MoCA score 26–30 points Tracks thinking benefit MoCA (Montreal Cognitive Assessment); conventional cutoff ≥26; alternate test versions limit practice effects
Pittsburgh Sleep Quality Index ≤5 points Tracks sleep effect PSQI (Pittsburgh Sleep Quality Index, a 19-item sleep questionnaire); higher scores are worse; conventional cutoff >5 indicates poor sleep; covers the prior month

Qualitative markers:

  • Mental clarity and ease of concentration during demanding work
  • Daytime energy and resistance to fatigue
  • Calmness under stress without drowsiness
  • Sleep onset and feeling rested on waking
  • Frequency of headaches, dizziness, flushing, or irritability

Emerging Research

  • No registered trials: A ClinicalTrials.gov search on 09/28/2026 found no registered picamilon trials, so no NCT ID exists; ongoing work appears only in Russian journals and registries, limiting outside verification.
  • Pooled Russian cerebral-ischemia data: An open 100-patient analysis of stage I and II chronic cerebral ischemia reported that over 80% reached normal MoCA ranges at follow-up, with larger gains in advanced disease (Danilov et al., 2025); it lacks a placebo arm.
  • Mechanism challenge: An FDA screen found intact picamilon inactive at 50 targets (Santillo & Sprando, 2023); together with the minimal brain GABA rise in mice (Matsuyama et al., 1984), this weakens the prodrug explanation and calls for human brain-metabolite studies.
  • Diabetic nervous-system protection: Rat studies show picamilon reduced nerve sugar-alcohol buildup, raised myelin protein, and preserved blood-brain barrier markers (Kuchmerovska et al., 2024; Tykhonenko et al., 2022); these effects are untested in humans.
  • Hybrid molecules: Researchers linked picamilon to the Alzheimer’s drug memantine, producing conjugates that protected cultured nerve cells (Chayrov et al., 2022); this is early drug-design work, not evidence for picamilon itself.
  • Decisive future research: Blinded, placebo-controlled trials in cognitively healthy older adults, run independently of the manufacturer and paired with human pharmacokinetic (absorption and clearance) and brain-GABA measurements, could either confirm modest benefits or show that the Russian findings reflect open-label bias.

Conclusion

Picamilon is a Soviet-era compound that joins niacin to the brain’s main calming messenger. It is a prescription medication in Russia and is sold unlawfully as a supplement in the United States. For health-focused adults thinking about brain aging, the most relevant evidence is modest: a Russian trial funded by the drug’s manufacturer, in which patients and doctors knew the treatment, found slightly better thinking scores when picamilon was added to ginkgo in people with long-standing blood-vessel disease of the brain. Smaller studies without comparison groups describe better sleep, calmer mood, and less fatigue. No study has tested it in healthy adults.

Reported side effects are generally mild, such as headache, dizziness, irritability, and flushing, but long-term safety is unstudied, Russian labeling excludes kidney disease and pregnancy, and it may strengthen strong pain medications and other calming drugs. The largest practical hazard is product quality: supplements tested in the United States ranged from almost none to several times the prescription amount, sometimes alongside other unapproved drugs.

How picamilon works is itself uncertain: laboratory work by a U.S. regulator with no commercial stake found that the intact compound acts on none of the many body targets it tested, and an older animal study found little release of its calming component in the brain, while early Western enthusiasm came partly from a supplement company and websites earning sales commissions. Overall, the evidence base is small, mostly Russian-language, and partly manufacturer-linked, leaving its value for healthy aging plausible but unconfirmed.

Top - Benefits - Risks - Protocol